Compare OXM & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OXM | OMER |
|---|---|---|
| Founded | 1942 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.3M | 772.8M |
| IPO Year | 1994 | 2008 |
| Metric | OXM | OMER |
|---|---|---|
| Price | $35.82 | $10.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $38.00 | $32.50 |
| AVG Volume (30 Days) | 579.1K | ★ 2.0M |
| Earning Date | 06-10-2026 | 05-14-2026 |
| Dividend Yield | ★ 6.80% | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | ★ 1.00 | 0.62 |
| Revenue | ★ $1,477,834,000.00 | $29,868,000.00 |
| Revenue This Year | $2.85 | N/A |
| Revenue Next Year | $2.63 | $233.22 |
| P/E Ratio | $38.14 | ★ $16.90 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.57 | $2.95 |
| 52 Week High | $51.61 | $17.65 |
| Indicator | OXM | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 46.63 |
| Support Level | $33.84 | $9.54 |
| Resistance Level | $41.58 | $12.06 |
| Average True Range (ATR) | 2.57 | 0.81 |
| MACD | -0.54 | 0.18 |
| Stochastic Oscillator | 8.28 | 91.21 |
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company's business is organized as: Tommy Bahama, Lilly Pulitzer, Johnny Was and Emerging Brands reportable segments. Geographically, the company operates in United States as well as Internationally.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.